• Mon news: Autolus enters CAR-T race with FDA approval. FDA clears clinical hold on Novavax. AbbVie schizophrenia trial failure. Cigna not pursuing Humana. GSK leaving BIO. See more on our front page

#ASCO21: AstraZeneca's PD-1 Imfinzi tacks on 5-year survival data in NSCLC, which...

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Jun 04, 2021 at 11:12: AM
via Amid a sea of competitors in PD-1, AstraZeneca has looked to outrun the big dogs in Merck and Bristol Myers Squibb with its Imfinzi. One way to differentiate? Long-term effect — and now AstraZeneca has five-year data in NSCLC it thinks can set its drug apart.

article source
 




Top Bottom
Back
Quote